U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Protein Kinase Inhibitors [Pharmacological Action]

Tree Number(s): D047428

MeSH Unique ID: D047428

  • N(6),N(6)-dimethyladenine (Supplementary Concept)
  • adenosine-3',5'-cyclic phosphorothioate (Supplementary Concept)
  • N-(2-guanidinoethyl)-5-isoquinolinesulfonamide (Supplementary Concept)
  • N-(2-aminoethyl)-5-isoquinolinesulfonamide (Supplementary Concept)
  • fasudil (Supplementary Concept)
  • N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide (Supplementary Concept)
  • 7-hydroxystaurosporine (Supplementary Concept)
  • midostaurin (Supplementary Concept)
  • calphostin D (Supplementary Concept)
  • protein kinase inhibitor peptide (Supplementary Concept)
  • protein kinase inhibitor peptide (1-31) (Supplementary Concept)
  • N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide (Supplementary Concept)
  • protein kinase inhibitor peptide (6-24) (Supplementary Concept)
  • protein kinase inhibitor M (6-24) (Supplementary Concept)
  • KN 93 (Supplementary Concept)
  • KT 5823 (Supplementary Concept)
  • alvocidib (Supplementary Concept)
  • 1-(5-isoquinolinylsulfonyl)-3-methylpiperazine (Supplementary Concept)
  • butyrolactone I (Supplementary Concept)
  • 9-phenanthrol (Supplementary Concept)
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one (Supplementary Concept)
  • 4,5-dianilinophthalimide (Supplementary Concept)
  • Pkia protein, mouse (Supplementary Concept)
  • PD 166866 (Supplementary Concept)
  • Semaxinib (Supplementary Concept)
  • CL 387785 (Supplementary Concept)
  • CGP 77675 (Supplementary Concept)
  • vatalanib (Supplementary Concept)
  • SB 239063 (Supplementary Concept)
  • PKI 166 (Supplementary Concept)
  • PD 180970 (Supplementary Concept)
  • orantinib (Supplementary Concept)
  • EKB 569 (Supplementary Concept)
  • 2-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimide (Supplementary Concept)
  • hesperadin (Supplementary Concept)
  • Pkia protein, rat (Supplementary Concept)
  • 2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide (Supplementary Concept)
  • palbociclib (Supplementary Concept)
  • cediranib (Supplementary Concept)
  • bafetinib (Supplementary Concept)
  • ON 01910 (Supplementary Concept)
  • 8-((3-bromophenyl)amino)-3-methyl-3H-imidazo(4,5-g)quinazoline (Supplementary Concept)
  • BKI1 protein, Arabidopsis (Supplementary Concept)
  • Pkig protein, mouse (Supplementary Concept)
  • dorsomorphin (Supplementary Concept)
  • protein kinase inhibitor peptide (5-24) (Supplementary Concept)
  • PF-670462 (Supplementary Concept)
  • MP 412 (Supplementary Concept)
  • nintedanib (Supplementary Concept)
  • lenvatinib (Supplementary Concept)
  • PF 00477736 (Supplementary Concept)
  • N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide (Supplementary Concept)
  • gedatolisib (Supplementary Concept)
  • KRP4 protein, Arabidopsis (Supplementary Concept)
  • N-(4-methyl-3-(1-methyl-7-(6-methylpyridin-3-ylamino)-2-oxo-1,2-dihydropyrimido(4,5-d)pyrimidin-3(4H)-yl)phenyl)-3-(trifluoromethyl)benzamide (Supplementary Concept)
  • tivozanib (Supplementary Concept)
  • apatinib (Supplementary Concept)
  • trametinib (Supplementary Concept)
  • dabrafenib (Supplementary Concept)
  • N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide (Supplementary Concept)
  • WZ4002 (Supplementary Concept)
  • XL647 (Supplementary Concept)
  • agerafenib (Supplementary Concept)
  • ilorasertib (Supplementary Concept)
  • AL622 (Supplementary Concept)
  • spebrutinib (Supplementary Concept)
  • ipatasertib (Supplementary Concept)
  • vactosertib (Supplementary Concept)
  • A-484954 (Supplementary Concept)
  • entrectinib (Supplementary Concept)
  • prexasertib (Supplementary Concept)
  • ravoxertinib (Supplementary Concept)
  • 2-((3-acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (Supplementary Concept)
  • CHMFL-FLT3-213 compound (Supplementary Concept)
  • motesanib diphosphate (Supplementary Concept)
  • OTS167 (Supplementary Concept)
  • rimacalib (Supplementary Concept)
  • 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (Supplementary Concept)
  • 1,2,4-triazolo-(3,4-b)-1,3,4-thiadiazoles (Supplementary Concept)
  • ONO-7579 (Supplementary Concept)
  • X480 (Supplementary Concept)
  • voruciclib (Supplementary Concept)
  • SHC004-221A1 (Supplementary Concept)
  • PF-5236216 (Supplementary Concept)
  • Debio 0617B (Supplementary Concept)
  • GSK2636771 (Supplementary Concept)
  • 3,4-diaminonaphthalene-2,7-disulfonic acid (Supplementary Concept)
  • NTRC 0066-0 (Supplementary Concept)
  • rebastinib (Supplementary Concept)
  • naquotinib (Supplementary Concept)
  • PF-04802367 (Supplementary Concept)
  • (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (Supplementary Concept)
  • GDC-0575 (Supplementary Concept)
  • A131 compound (Supplementary Concept)
  • acrizanib (Supplementary Concept)
  • 4-(2,3-dihydro-1H-benzo(d)pyrrolo(1,2-a)imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine (Supplementary Concept)
  • JH-VIII-157-02 (Supplementary Concept)
  • UM-164 (Supplementary Concept)
  • AZD7624 (Supplementary Concept)
  • deucravacitinib (Supplementary Concept)
  • AZ31 compound (Supplementary Concept)
  • GNE-924 (Supplementary Concept)
  • 4-ethoxy-7H-pyrrolo(2,3-d)pyrimidin-2-amine (Supplementary Concept)
  • (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (Supplementary Concept)
  • ensartinib (Supplementary Concept)
  • KAN0439834 (Supplementary Concept)
  • 2 (4'-hydroxynaphthyl) chromen-4-one (Supplementary Concept)
  • 6,7-dimethoxy-4-anilinoquinoline (Supplementary Concept)
  • tryptanthrin-6-oxime (Supplementary Concept)
  • CAM187 (Supplementary Concept)
  • INCB 54828-101 (Supplementary Concept)
  • GADD45beta-I (Supplementary Concept)
  • Nemiralisib (Supplementary Concept)
  • CL27c (Supplementary Concept)
  • KX2-361 (Supplementary Concept)
  • IkK-16 compound (Supplementary Concept)
  • AZD-0424 (Supplementary Concept)
  • PF-06700841 (Supplementary Concept)
  • GSK2646264 (Supplementary Concept)
  • FF-10101 (Supplementary Concept)
  • AZD0156 (Supplementary Concept)
  • GS-680 (Supplementary Concept)
  • LIMKi3 (Supplementary Concept)
  • RapaLink-1 (Supplementary Concept)
  • abrocitinib (Supplementary Concept)
  • selonsertib (Supplementary Concept)
  • R333 (Supplementary Concept)
  • tucatinib (Supplementary Concept)
  • JTE-952 (Supplementary Concept)
  • GSK3186899 (Supplementary Concept)
  • chiauranib (Supplementary Concept)
  • aflutinib (Supplementary Concept)
  • AZD7648 (Supplementary Concept)
  • belizatinib (Supplementary Concept)
  • TAS-121 (Supplementary Concept)
  • onvansertib (Supplementary Concept)
  • LN950 (Supplementary Concept)
  • TAK1 inhibitor NG25 (Supplementary Concept)
  • AZ5104 (Supplementary Concept)
  • YKL-5-124 (Supplementary Concept)
  • YKL-05-099 (Supplementary Concept)
  • IBL-302 (Supplementary Concept)
  • lazertinib (Supplementary Concept)
  • TKM-080301 (Supplementary Concept)
  • KIRA6 (Supplementary Concept)
  • vorolanib (Supplementary Concept)
  • PFE-360 (Supplementary Concept)
  • branebrutinib (Supplementary Concept)
  • acumapimod (Supplementary Concept)
  • senexin A (Supplementary Concept)
  • conteltinib (Supplementary Concept)
  • peposertib (Supplementary Concept)
  • JNK-IN-8 (Supplementary Concept)
  • belumosudil (Supplementary Concept)
  • LS-106 (Supplementary Concept)
  • PRN473 (Supplementary Concept)
  • remibrutinib (Supplementary Concept)
  • TAS-119 (Supplementary Concept)
  • naporafenib (Supplementary Concept)
  • LPM4870108 (Supplementary Concept)
  • LUT014 (Supplementary Concept)
  • OATD-01 (Supplementary Concept)
  • Sniper(tacc3)-2 (Supplementary Concept)
  • zabedosertib (Supplementary Concept)
  • Emodin (MeSH Term)
  • Genistein (MeSH Term)
  • Phosphatidylethanolamine Binding Protein (MeSH Term)
  • Cyclin-Dependent Kinase Inhibitor Proteins (MeSH Term)
  • Cyclin-Dependent Kinase Inhibitor p21 (MeSH Term)
  • Cyclin-Dependent Kinase Inhibitor p27 (MeSH Term)
  • Cyclin-Dependent Kinase Inhibitor p57 (MeSH Term)
  • Cyclin-Dependent Kinase Inhibitor p15 (MeSH Term)
  • Cyclin-Dependent Kinase Inhibitor p18 (MeSH Term)
  • Cyclin-Dependent Kinase Inhibitor p19 (MeSH Term)
  • Sorafenib (MeSH Term)
  • Wortmannin (MeSH Term)
  • Sunitinib (MeSH Term)
  • Vemurafenib (MeSH Term)
  • Roscovitine (MeSH Term)
  • Axitinib (MeSH Term)
  • upadacitinib (Supplementary Concept)
  • tofacitinib (Supplementary Concept)
  • temsirolimus (Supplementary Concept)
  • osimertinib (Supplementary Concept)
  • acalabrutinib (Supplementary Concept)
  • gilteritinib (Supplementary Concept)
  • 1-(3-(2H-1,2,3-triazol-2-yl)phenyl)-N-6-(2-aminocyclohexyl)-1H-pyrazolo(3,4-b)pyrazine-3,6-diamine (Supplementary Concept)
  • asciminib (Supplementary Concept)
  • 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine (Supplementary Concept)
  • (6,7-dimethoxy-2,4-dihydroindeno(1,2-c)pyrazol-3-yl)(3-fluorophenyl)amine (Supplementary Concept)
  • dacomitinib (Supplementary Concept)
  • bosutinib (Supplementary Concept)
  • ibrutinib (Supplementary Concept)
  • flumatinib (Supplementary Concept)
  • EGFR tyrosine kinase inhibitor 324674 (Supplementary Concept)
  • G6 stilbenoid tyrosine kinase inhibitor (Supplementary Concept)
  • (4-(4-(6-amino-5-(benzo(d)oxazol-2-yl)pyridin-3-yl)-1H-pyrazol-1-yl)piperidin-1-yl)ethanone (Supplementary Concept)
  • alectinib (Supplementary Concept)
  • mobocertinib (Supplementary Concept)
  • pirtobrutinib (Supplementary Concept)
  • zanubrutinib (Supplementary Concept)
  • abivertinib (Supplementary Concept)
  • quizartinib (Supplementary Concept)
  • ponatinib (Supplementary Concept)
  • neratinib (Supplementary Concept)
  • nilotinib (Supplementary Concept)
  • ceritinib (Supplementary Concept)
  • Everolimus (MeSH Term)
  • Imatinib Mesylate (MeSH Term)
  • Erlotinib Hydrochloride (MeSH Term)
  • Dasatinib (MeSH Term)
  • Gefitinib (MeSH Term)
  • Lapatinib (MeSH Term)
  • Afatinib (MeSH Term)
  • Crizotinib (MeSH Term)

Supplemental Content

Loading ...